LifeSci Acquisition in a definitive proxy filing set a Dec. 22 meeting for shareholders to vote on the SPAC’s proposed merger with Vincera Pharma. The combined company is expected to have approximately $60 million in cash at closing if shareholders approve the deal. LifeSCi said as of Dec. 3 there was approximately $65.7 million held in trust. Read more.
LifeSci Sets Vote on Vincera Pharma Merger Plan
